Preoperative Corneal Measurements Estimate the Corrected Distance Visual Acuity After Corneal Cross-linking
NCT ID: NCT06522789
Last Updated: 2024-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
124 participants
INTERVENTIONAL
2018-04-01
2023-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Accuracy of Curvature and Wavefront Aberrations of Posterior Corneal Surface, in Keratoconic and Post-CXL Corneas
NCT01527708
Corneal Thickness Changes During Corneal Collagen Cross-linking With Ultraviolet-A Irradiation and Riboflavin
NCT01485211
One-Year Outcomes After Conventional vs Accelerated Epi-Off Corneal Cross-Linking in Progressive Keratoconus (Observational Cohort)
NCT07194538
Blurring Strength & Aberrometric Changes Following Corneal Cross-linking (CxL) and CxL Combined With Photorefractive Keratectomy (PRK) in Keratoconus
NCT01527721
Evaluation of the Keratoconic Cornea After Corneal Collagen Cross Linking.
NCT03879421
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The patients' examination before the treatment and on every follow-up was a meticulous process that included assessment of CDVA (Aitomu LCD Digital Vision Eye Chart, Shanghai, China), refraction, tonometry, and corneal characteristics using Pentacam HR (Oculus, Optikgeräte GmbH, Wetzlar, Germany), biomicroscopy and dilated fundus examination. Corneal topography, thickness distribution, and COD profiles were captured for later analysis. The COD profile, which describes the turbidity of the cornea in the central apical region and the three concentric annular zones, was a vital part of the examination. The Pentacam software computed a figure, ranging from 0 (totally clear) to 100 (totally opaque), along a grey scale describing the optical density in each of the 12 regions. A higher number signifies increased turbidity and reduced transparency; a lower number represents the opposite. The software also averaged the total optical density in the apex, each concentric zone, each layer, and the cornea. A total of 20 COD values are generated for a single cornea. COD values for the central 0-2mm region covering the anterior (0-2ant) and central layers (0-2cent), paracentral 2-6mm annulus covering the anterior (2-6ant) and central layers (2-6cent), total anterior region layer (tot ant), total central layer (tot cent), and whole cornea (tot) were recorded. Separate COD values for the peripheral (6-10mm and 10-12mm annuli) and posterior (60µ) regions of the cornea were excluded as these regions are least likely to be affected by CXL. On all occasions, three consecutive Pentacam scans were taken in a dark room, and the best-quality scan was selected for recording and analysis. For each case, the COD (in greyscale units), thinnest corneal thickness (TCT, µ), anterior (ARC) and posterior (PRC) corneal radii of curvature(mm) values measured over a 3mm diameter zone covering the cone of the cornea were sequestered from the best scan.
The CXL procedure for group one adhered to the standard Dresden protocol. All patients received topical anaesthetic (Tetracaine HCL 0.5%, Alcon Forth Worth, Texas) and a miotic (Isopto Carpine 2% HCl, Alcon, Fort Worth, Texas) drops 30 minutes before the procedure. The periocular region and conjunctival sac were washed with 10% povidone-iodine (Betadine 10%, Alcaloid, Skopje). Manual epithelial scraping with a crescent knife followed. Pachymetry was kept over 400 μm during the procedure and measured with an ultrasound hand pachymeter (Pocket II, Quantel Medical, Cournon d'Auvergne, France). Riboflavin (Peschke D, Peschke Trade, Huenenberg, Switzerland) was applied every 3 minutes for 30 minutes. We performed corneal UV-A radiation with a wavelength of 370 nm and energy of 3mW using a UVA CXL lamp (VEGA CBM-X-Linker, Carleton Optical, Chesham, UK) for 30 minutes (6 cycles of 5 minutes each). Device testing was performed before every procedure, and irradiance density measured between 2.7-and-3.3 mW/cm2 was tolerated. At the end of the corneal CXL procedure, topical atropine 1% (Atropine Sulphate, Cooper, Athens, Greece), antibiotic (Tobrex, Alcon, Fort Worth, Texas) drops were instilled and a bandage soft contact lens (Air Optix Night \& Day Aqua, Alcon, Texas) was placed over the cornea. Peschke® D. Riboflavin used in the study group was a standard Riboflavin solution consisting of 0.1% Riboflavin diluted into 20% dextran 500. The soaking time was 20-30 minutes or until microscopy showed riboflavin particles in the anterior chamber. Tobradex (Alcon, Fort Worth, Texas) eyedrops, a suspension of 0.3% Tobramycine and 0.05% Dexamethasone were prescribed for application after CXL. The dosage was four times per day for the first two weeks, then tapered twice daily for the next two weeks, and then to one drop per day for the last two weeks. All patients received topical steroids for a total of 6 weeks.
The postoperative care was comprehensive, ensuring the patient's well-being and recovery. It included a combination of antibiotic/corticosteroid drops instilled four times daily for the next two weeks, after which the drops were tapered off gradually over six weeks. Postoperative examinations were scheduled for one day, four days, 1-week until epithelisation and bandage lens removal, then 1-,3-,6-months, and 1-year postoperatively. After that, the patients were advised to complete an ophthalmological examination at least yearly.
Data from the treated eye, or just the right eye in bilateral cases, were analysed. Details of CDVA, COD, TCT, ARC and PRC values were stored in Excel (Microsoft, Redmond, WA) and analysed to determine the significance of any differences between groups (Mann Whitney U test or unpaired t-test) and changes occurring within each group (Friedman test or 1-way ANOVA for repeat measures, Wilcoxon signed rank or paired t-test). If significant changes were found, then the analysis would be extended to determine the significance of any association between the change (i.e., preop value-postop value) in the parameter and the value at the start of the study (Spearman's rho or Pearson correlation). Depending on the outcome of this analysis, the data would be further scrutinised to determine if a feasible model could be constructed (linear and multiple regression analysis) to predict the likely CDVA after CXL or after one year in untreated cases. Non-parametric tests were applied when data were not normally distributed (Kolmogorov-Smirnov test of normality). The changes and differences were considered statistically significant when p˂0.05.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
The total number of patients who underwent CXL was seventy-seven; 23 were females, and 54 were males of the mean (±sd, range) age 24.2 (±7.0, 11-44) years.
corneal cross-linking procedure
Standard Dresden protocol corneal cross-linking procedure The CXL procedure adhered to the standard Dresden protocol. All patients received topical anaesthetic (Tetracaine HCL 0.5%, Alcon Forth Worth, Texas) and a miotic (Isopto Carpine 2% HCl, Alcon, Fort Worth, Texas) drops 30 minutes before the procedure. The periocular region and conjunctival sac were washed with 10% povidone-iodine (Betadine 10%, Alcaloid, Skopje). Manual epithelial scraping with a crescent knife followed. Pachymetry was kept over 400 μm during the procedure and measured with an ultrasound hand pachymeter (Pocket II, Quantel Medical, Cournon d'Auvergne, France). Riboflavin (Peschke D, Peschke Trade, Huenenberg, Switzerland) was applied every 3 minutes for 30 minutes. We performed corneal UV-A radiation with a wavelength of 370 nm and energy of 3mW using a UVA CXL lamp (VEGA CBM-X-Linker, Carleton Optical, Chesham, UK) for 30 minutes (6 cycles of 5 minutes each).
Group 2
Twenty-three patients, six females and 17 males of mean age 27.3 (±7.0, 17-44) years, were untreated.
No interventions assigned to this group
Group 3
Twenty-four subjects, nine females and 15 males of mean age 24.7 (±7.6, 17-45) years, were recruited as controls.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
corneal cross-linking procedure
Standard Dresden protocol corneal cross-linking procedure The CXL procedure adhered to the standard Dresden protocol. All patients received topical anaesthetic (Tetracaine HCL 0.5%, Alcon Forth Worth, Texas) and a miotic (Isopto Carpine 2% HCl, Alcon, Fort Worth, Texas) drops 30 minutes before the procedure. The periocular region and conjunctival sac were washed with 10% povidone-iodine (Betadine 10%, Alcaloid, Skopje). Manual epithelial scraping with a crescent knife followed. Pachymetry was kept over 400 μm during the procedure and measured with an ultrasound hand pachymeter (Pocket II, Quantel Medical, Cournon d'Auvergne, France). Riboflavin (Peschke D, Peschke Trade, Huenenberg, Switzerland) was applied every 3 minutes for 30 minutes. We performed corneal UV-A radiation with a wavelength of 370 nm and energy of 3mW using a UVA CXL lamp (VEGA CBM-X-Linker, Carleton Optical, Chesham, UK) for 30 minutes (6 cycles of 5 minutes each).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Group 2 subjects consisted of confirmed keratoconus without signs of progression who opted to continue with their prescription glasses and tear-enhancing drops where necessary
* Group 3 is a control group of age- and gender-matched individuals without signs of keratoconus.
Exclusion Criteria
11 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sistina Ophthalmology Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fanka Gilevska
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fanka Gilevska, PhD cand
Role: PRINCIPAL_INVESTIGATOR
Sistina Ophthalmology Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fanka Gilevska
Skopje, , North Macedonia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gilevska F, Biscevic A, Bohac M, Patel S. Could Automated Objective Measurements Acquired at the Preoperative Stage Estimate the Corrected Distance Visual Acuity after Corneal Cross-Linking in Keratoconus? Ophthalmol Ther. 2024 Oct;13(10):2599-2614. doi: 10.1007/s40123-024-00993-0. Epub 2024 Aug 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17-25 10.02.2017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.